{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:02Z","timestamp":1792036862163,"version":"4.4.0"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>B-cell maturation antigen (BCMA) is the target of several investigational and approved drugs for multiple myeloma. BCMA expressed on plasma cells (PC) and multiple myeloma cells is cleaved by the enzyme \u03b3-secretase, reducing membrane-bound BCMA (mbBCMA) receptor density. \u03b3-Secretase inhibitors (GSI) have been shown to increase mbBCMA density and may enhance efficacy of BCMA-targeted therapies. The pharmacodynamic profile of the GSI nirogacestat was evaluated in multiple myeloma cell lines and a phase I study in healthy volunteers. In multiple myeloma cell lines, mbBCMA density and soluble BCMA concentrations were measured before and after short-duration nirogacestat exposure and at serial time points following washout. In the phase I study, 23 participants were administered a single oral dose of nirogacestat 50, 150, or 300 mg or repeated doses of 100 mg every 12 hours for up to 48 hours; mbBCMA density on PCs (from whole blood and bone marrow) and nirogacestat plasma concentrations were measured at baseline and postdose. After single-dose administration, serum nirogacestat concentrations rapidly increased (Tmax \u223c1 hour), and a two-compartment model with linear absorption and clearance best described nirogacestat pharmacokinetics. In multiple myeloma cells and healthy volunteers\u2019 PCs, nirogacestat resulted in rapid and robust increases in mbBCMA density, with increases up to 20-fold within 4 to 8 hours of exposure. Concomitant decreases in soluble BCMA were observed. Nirogacestat is currently being evaluated in combination with several BCMA-directed therapeutic agents in patients with multiple myeloma. Elucidating the kinetics of BCMA in response to nirogacestat is key to guiding dosing and therapeutic strategies in multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>GSIs can enhance multiple myeloma therapies targeting BCMA by increasing mbBCMA on plasma cells. In response to the GSI nirogacestat, mbBCMA rapidly and robustly increased in vitro and in vivo. Elucidating nirogacestat\u2019s effects on BCMA kinetics will guide potential multiple myeloma dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0075","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T09:02:58Z","timestamp":1731402178000},"page":"3114-3123","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6106-2778","authenticated-orcid":false,"given":"Todd","family":"Shearer","sequence":"first","affiliation":[{"name":"1SpringWorks Therapeutics, Inc., Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0393-9571","authenticated-orcid":false,"given":"Melissa","family":"Comstock","sequence":"additional","affiliation":[{"name":"2Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1839-2925","authenticated-orcid":false,"suffix":"Jr","given":"Rex L.","family":"Williams","sequence":"additional","affiliation":[{"name":"1SpringWorks Therapeutics, Inc., Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0603-1937","authenticated-orcid":false,"given":"Mark C.","family":"Johnson","sequence":"additional","affiliation":[{"name":"1SpringWorks Therapeutics, Inc., Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-228X","authenticated-orcid":false,"given":"Ewa","family":"Cendrowicz","sequence":"additional","affiliation":[{"name":"3ICON BioAnalytical Laboratories, Assen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1964-2461","authenticated-orcid":false,"given":"Cathrine","family":"Leonowens","sequence":"additional","affiliation":[{"name":"4Independent Consultant, Sanford, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9875-7657","authenticated-orcid":false,"given":"Margaret","family":"Smith","sequence":"additional","affiliation":[{"name":"1SpringWorks Therapeutics, Inc., Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0127-8930","authenticated-orcid":false,"given":"Todd M.","family":"Baughman","sequence":"additional","affiliation":[{"name":"1SpringWorks Therapeutics, Inc., Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5731-1163","authenticated-orcid":false,"given":"Caroline J.","family":"Breitbach","sequence":"additional","affiliation":[{"name":"1SpringWorks Therapeutics, Inc., Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4924-6567","authenticated-orcid":false,"given":"Shinta","family":"Cheng","sequence":"additional","affiliation":[{"name":"1SpringWorks Therapeutics, Inc., Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1446","authenticated-orcid":false,"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"2Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington."},{"name":"5Division of Transplantation and Cellular Therapy, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"2025051308420336300_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025051308420336300_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"2025051308420336300_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"2025051308420336300_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"2025051308420336300_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"2025051308420336300_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"2025051308420336300_bib7","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"2025051308420336300_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms24010645","article-title":"Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance","volume":"24","author":"De Novellis","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025051308420336300_bib9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"2025051308420336300_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025051308420336300_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"2025051308420336300_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025051308420336300_bib13","first-page":"279","article-title":"Precision medicine for human cancers with Notch signaling dysregulation (Review)","volume":"45","author":"Katoh","year":"2020","journal-title":"Int J Mol Med"},{"key":"2025051308420336300_bib14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2022.281339","article-title":"All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells","volume":"108","author":"Garc\u00eda-Guerrero","year":"2023","journal-title":"Haematologica"},{"key":"2025051308420336300_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"},{"key":"2025051308420336300_bib16","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1002\/cncr.34332","article-title":"Evolving strategies for management of desmoid tumor","volume":"128","author":"Riedel","year":"2022","journal-title":"Cancer"},{"key":"2025051308420336300_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N Engl J Med"},{"key":"2025051308420336300_bib18","volume-title":"Nirogacestat (OGSIVEO) [Prescribing Information]","author":"OGSIVEO"},{"issue":"suppl 16","key":"2025051308420336300_bib19","doi-asserted-by":"publisher","first-page":"abstr 8019","DOI":"10.1200\/JCO.2022.40.16_suppl.8019","article-title":"Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-5 study","volume":"40","author":"Lonial","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025051308420336300_bib20","doi-asserted-by":"publisher","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"Teclistamab (TEC) + nirogacestat (NIRO) in relapsed\/refractory multiple myeloma (RRMM): the phase 1b MajesTEC-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"Hemasphere"},{"key":"2025051308420336300_bib21","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025051308420336300_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"MAbs"},{"key":"2025051308420336300_bib23","doi-asserted-by":"crossref","first-page":"e005403","DOI":"10.1136\/jitc-2022-005403","article-title":"Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report","volume":"10","author":"Li","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025051308420336300_bib24","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"2025051308420336300_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0075\/3517389\/crc-24-0075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/12\/3114\/3525116\/crc-24-0075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/12\/3114\/3525116\/crc-24-0075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:42:55Z","timestamp":1747125775000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/12\/3114\/750524\/Kinetics-of-Nirogacestat-Mediated-Increases-in-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0075","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29049933","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049945","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006917","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006929","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006905","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728070","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049951","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728046","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728058","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728064","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728040","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728052","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728037","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728049","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006896","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049939","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006941","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006935","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006947","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006911","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049957","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006923","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728061","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049954","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006926","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049942","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006938","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049930","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006908","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049960","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728055","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728067","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728043","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006920","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006932","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006902","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049948","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006914","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28006944","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29049936","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7579743","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}